Brief: Parabilis Medicines Initiates Dose-Ranging Clinical Study Of Zolucatetide In Familial Adenomatous Polyposis
14/10/2026 13:37
BRIEF-Parabilis Medicines Initiates Dose-Ranging Clinical Study Of Zolucatetide In Familial Adenomatous Polyposis Oct 14 (Reuters) - Parabilis Medicines Inc PBLS.O:
PARABILIS MEDICINES INITIATES DOSE-RANGING CLINICAL STUDY OF ZOLUCATETIDE IN FAMILIAL ADENOMATOUS POLYPOSIS
PARABILIS MEDICINES - TO DISCLOSE ADDITIONAL FAP DATA FROM PHASE 1/2 TRIAL IN Q1 2027
Source text: ID:nGNX8mdVVc
Further company coverage: PBLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Parabilis Medicines
See all newsBrief: Parabilis Medicines Initiates Dose-Ranging Clinical Study Of Zolucatetide In Familial Adenomatous Polyposis
Brief: Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates
Brief: Alphabet Reports Share Stake In SpaceX, Fervo Energy And Parabilis Medicines
U.S. RESEARCH ROUNDUP-East West Bancorp, First Citizens Bancshares, UMB Financial